Erstlinientherapie des behandlungsbedürftigen Multiplen Myeloms: Aktuelle Empfehlungen
Due to the introduction of novel therapeutic agents, the prognosis of Multiple Myeloma has greatly improved over the last decades. The current standard for fit patients is a bortezomib-based induction therapy, followed by high-dose chemotherapy and autologous stem cell transplantation and lenalidomi...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Deutsch |
| Veröffentlicht: |
2020
|
| In: |
Deutsche medizinische Wochenschrift
Year: 2020, Jahrgang: 145, Heft: 12, Pages: 813-819 |
| ISSN: | 1439-4413 |
| DOI: | 10.1055/a-1009-5756 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1055/a-1009-5756 Verlag, lizenzpflichtig, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/a-1009-5756 
|
| Verfasserangaben: | Lukas John, Hartmut Goldschmidt, Christof Scheid |
| Zusammenfassung: | Due to the introduction of novel therapeutic agents, the prognosis of Multiple Myeloma has greatly improved over the last decades. The current standard for fit patients is a bortezomib-based induction therapy, followed by high-dose chemotherapy and autologous stem cell transplantation and lenalidomide-based maintenance therapy. For older, non-transplant-eligible patients, daratumumab in combination with bortezomib or lenalidomide offers a well-tolerated, effective treatment option. Despite large improvements, there is still no cure for most myeloma patients, the aim of therapy is therefore to reach a deep remission to prevent lasting damage followed by a continuous maintenance therapy to uphold the remission and prolong overall survival. |
|---|---|
| Beschreibung: | Gesehen am 02.06.2021 |
| Beschreibung: | Online Resource |
| ISSN: | 1439-4413 |
| DOI: | 10.1055/a-1009-5756 |